Business ❯ Pharmaceuticals

Market Analysis

Company Performance Stock Performance Drug Sales Sales to Government Product Development Revenue Trends Drug Approval Clinical Trials Financial Outlook Financial Projections

Senior Source Says There Were No AstraZeneca‑Bristol Myers Merger Talks

The denial calmed markets yet left regulatory overlap and looming drug patent expiries as the main barriers to any large combination.

FDA Panel Weighs Moderna’s Bid for First U.S. mRNA Flu Vaccine

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

Sun Pharma Logs Modest Q2 Growth as U.S. Innovator Drugs Overtake Generics; Lupin Profit Jumps on Strong U.S. Demand

Rubicon Research IPO Opens Half Subscribed on Day One, Grey-Market Premium Near 20%

ICRA Sees Indian Pharma Growing 7–9% in FY26 as US Momentum Cools

Investec Upgrades Lupin to Buy, Raises Target as Shares Gain About 3%

FDA Approves Papzimeos as First Therapy for Adult Recurrent Respiratory Papillomatosis

Gland Pharma Q1 Profit Surges 50% as Brokerages Differ on Target Prices

BC Investments IV to Sell 2.4% Stake in Emcure Pharma Through Block Deal

Alembic Pharma Secures USFDA Approval for Liposomal Doxorubicin ANDA

Gland Pharma Q4 FY25 Results Miss Estimates as US Revenue Declines

Cipla Reports 30% YoY Profit Growth in Q4 FY25, Announces Rs 16 Dividend

Eli Lilly Lowers 2024 Revenue Forecast Due to Slower Weight-Loss Drug Growth

CDC Updates RSV Vaccine Guidance for Older Adults